1. Scrip
  2. >>R&D

Tuberculosis: An Old Killer Proving Difficult To Best

 
• By Benjamin Graham

With the announcement that tuberculosis surpassed HIV/AIDS in attributable deaths from infectious diseases worldwide, there has been a renewed interest in the development of new treatments and regimens for dealing with what is now the world’s number one infectious disease killer.

In 2015, the number of tuberculosis (TB) attributed deaths totalled 1.5 million, outnumbering the 1.2 million deaths due to HIV. While this represents a 47% fall in mortality from TB since 1990, the World Health Organization (WHO) estimates that the vast majority of deaths that occurred were preventable, which is problematic given the estimated 9.6 million new cases of TB in 2015 alone.

Tuberculosis is a contagious airborne disease caused by the bacterium Mycobacterium tuberculosis. It is largely a respiratory infection and up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial